title: Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma.
abstract: Accumulative data have demonstrated that plasminogen activator inhibitor-1 (PAI-1) plays an important role in the extracellular matrix metabolism; however, the involvement of PAI-1 in scleroderma has not been fully elucidated. In this study, we investigated the role of PAI-1 in bleomycin-induced murine scleroderma. 100 microg of bleomycin was injected subcutaneously to the back skin of C3H/HeJ mice on alternate day for 4 weeks. Histopathological findings revealed that PAI-1 was positive in macrophage-like cells and fibroblastic cells in the dermis, in parallel with the induction of dermal sclerosis. PAI-1 mRNA expression in the whole skin was up-regulated at 1 and 4 weeks. The production of active PAI-1 protein in the lesional skin was significantly increased 3 and 4 weeks after bleomycin treatment. Next, we examined whether dermal sclerosis is induced by bleomycin in PAI-1-deficient (PAI-1-/-) mice. 10 microg of bleomycin was subcutaneously injected to PAI-1-/- and wild type (WT) mice 5 days per week for 4 weeks. Histological examination revealed that dermal sclerosis was similarly induced even in PAI-1-/- as well as WT mice. Dermal thickness and collagen contents in the skin were significantly increased by bleomycin injection in both PAI-1-/- and WT mice, and the rate of increase was similar. These data suggest that PAI-1 plays an important role, possibly via TGF-beta pathway activation. However, the fact that PAI-1 deficiency did not ameliorate skin sclerosis suggest that PAI-1 is not the essential factor in the development of bleomycin-induced scleroderma, and more complex biochemical effects other than PA/plasmin system are greatly suspected.
authors.affiliation: Department of Dermatology, Tokyo Medical and Dental University, School of Medicine, Tokyo, Japan. mariko.derm@tmd.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Matsushita
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Nishioka
mesh_terms: D000818:Animals; D001761:Bleomycin; D003094:Collagen / Q000032:analysis; D020405:Dermis / Q000737:chemistry* / Q000473:pathology; D005260:Female; D005347:Fibroblasts / Q000737:chemistry; D006651:Histocytochemistry / Q000379:methods; D008264:Macrophages / Q000737:chemistry; D051379:Mice; D008809:Mice, Inbred C3H; D018345:Mice, Knockout; D023421:Models, Animal; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012595:Scleroderma, Systemic / Q000378:metabolism* / Q000473:pathology; D013047:Specific Pathogen-Free Organisms
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D001761:Bleomycin; D003094:Collagen
references.citation: J Hepatol. 1999 Oct;31(4):703-11
references.pmid: 10551395
references.citation: Hum Gene Ther. 1999 Sep 20;10(14):2315-23
references.pmid: 10515451
references.citation: Am J Pathol. 2000 Jul;157(1):177-87
references.pmid: 10880388
references.citation: Arch Dermatol Res. 2000 Nov;292(11):535-41
references.pmid: 11194891
references.citation: J Invest Dermatol. 2001 Oct;117(4):999-1001
references.pmid: 11676849
references.citation: Am J Pathol. 2001 Nov;159(5):1681-8
references.pmid: 11696429
references.citation: Clin Immunol. 2002 Jan;102(1):77-83
references.pmid: 11781070
references.citation: Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3908-13
references.pmid: 11904440
references.citation: Am J Respir Cell Mol Biol. 2002 Aug;27(2):141-50
references.pmid: 12151305
references.citation: FASEB J. 2003 Oct;17(13):1904-6
references.pmid: 12897066
references.citation: J Am Soc Nephrol. 2003 Dec;14(12):3047-60
references.pmid: 14638904
references.citation: J Rheumatol. 1985 Jun;12(3):514-7
references.pmid: 2931522
references.citation: Exp Cell Res. 1986 Jun;164(2):399-407
references.pmid: 3519251
references.citation: J Biol Chem. 1986 Aug 25;261(24):11207-13
references.pmid: 3090045
references.citation: J Cell Biol. 1986 Dec;103(6 Pt 1):2403-10
references.pmid: 3491081
references.citation: J Clin Invest. 1987 Apr;79(4):1285-8
references.pmid: 3470308
references.citation: EMBO J. 1987 Jul;6(7):1899-904
references.pmid: 2820711
references.citation: J Biol Chem. 1987 Dec 25;262(36):17467-74
references.pmid: 3121597
references.citation: Biochem J. 1987 Nov 1;247(3):597-604
references.pmid: 3501287
references.citation: J Biol Chem. 1988 Mar 5;263(7):3111-5
references.pmid: 3125175
references.citation: J Biol Chem. 1989 Jan 5;264(1):389-92
references.pmid: 2462560
references.citation: Connect Tissue Res. 1989;20(1-4):289-94
references.pmid: 2558843
references.citation: Biochim Biophys Acta. 1991 Sep 3;1094(2):207-10
references.pmid: 1654118
references.citation: Thromb Res. 1995 Mar 15;77(6):493-504
references.pmid: 7624837
references.citation: J Clin Invest. 1995 Sep;96(3):1621-30
references.pmid: 7544811
references.citation: J Clin Invest. 1996 Jan 1;97(1):232-7
references.pmid: 8550840
references.citation: Nat Med. 1996 Mar;2(3):287-92
references.pmid: 8612226
references.citation: J Invest Dermatol. 1996 May;106(5):1007-11
references.pmid: 8618030
references.citation: Br J Rheumatol. 1997 Oct;36(10):1045-50
references.pmid: 9374919
references.citation: Miner Electrolyte Metab. 1998;24(2-3):111-9
references.pmid: 9525693
references.citation: EMBO J. 1998 Jun 1;17(11):3091-100
references.pmid: 9606191
references.citation: Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1035-45
references.pmid: 9672063
references.citation: J Invest Dermatol. 1999 Apr;112(4):456-62
references.pmid: 10201529
references.citation: Exp Cell Res. 1999 May 1;248(2):634-42
references.pmid: 10222156
references.citation: J Rheumatol. 1999 Dec;26(12):2628-34
references.pmid: 10606374